{"DataElement":{"publicId":"3028678","version":"1","preferredName":"Gleason Score Prostate Cancer Timepoint Category","preferredDefinition":"Text term to identify the time frame for a Gleason score assessment.","longName":"GLEA_SC_TMPT_CAT","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3028670","version":"1","preferredName":"Gleason Score Prostate Cancer Timepoint","preferredDefinition":"A system of grading prostate cancer cells to determine the best treatment and to predict how well a person is likely to do. A low Gleason score means the cancer cells are very similar to normal prostate cells; a high Gleason score means the cancer cells are very different from normal. _A specific point in the time continuum, including those established relative to an event.","longName":"GLEA_SC_TMPT","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2547908","version":"1","preferredName":"Gleason Score for Prostate Cancer","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","longName":"C28084","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23681B08-081C-19C0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-11-29","modifiedBy":"SBREXT","dateModified":"2017-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2661790","version":"1","preferredName":"Timepoint","preferredDefinition":"A specific point in the time continuum, including those established relative to an event.","longName":"C68568","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Timepoint","conceptCode":"C68568","definition":"A specific point in the time continuum, including those established relative to an event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"345BF7BD-4636-3CED-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-07-03","modifiedBy":"ONEDATA","dateModified":"2007-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"825F3F1F-3441-D22E-E040-BB89AD4374D6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3028672","version":"1","preferredName":"Gleason Score Prostate Cancer Timepoint Category","preferredDefinition":"A system of grading prostate cancer cells to determine the best treatment and to predict how well a person is likely to do. A low Gleason score means the cancer cells are very similar to normal prostate cells; a high Gleason score means the cancer cells are very different from normal._A specific point in the time continuum, including those established relative to an event._Category; used informally to mean a class of things.","longName":"GLEA_SC_TMPT_CAT","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"During follow-up","valueDescription":"During follow-up","ValueMeaning":{"publicId":"3028673","version":"1","preferredName":"During follow-up","longName":"3028673","preferredDefinition":"During follow-up","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"825F3F1F-347A-D22E-E040-BB89AD4374D6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"825F3F1F-3493-D22E-E040-BB89AD4374D6","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","deletedIndicator":"No"},{"value":"During radiotherapy","valueDescription":"During radiotherapy","ValueMeaning":{"publicId":"3028674","version":"1","preferredName":"During radiotherapy","longName":"3028674","preferredDefinition":"During radiotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"825F3F1F-349D-D22E-E040-BB89AD4374D6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"825F3F1F-34B6-D22E-E040-BB89AD4374D6","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","deletedIndicator":"No"},{"value":"During chemotherapy","valueDescription":"During chemotherapy","ValueMeaning":{"publicId":"2572006","version":"1","preferredName":"During chemotherapy","longName":"2572006","preferredDefinition":"During chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E653-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-10-07","modifiedBy":"SHIDED","dateModified":"2004-10-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"825F3F1F-34C0-D22E-E040-BB89AD4374D6","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","deletedIndicator":"No"},{"value":"At screening - prostatectomy","valueDescription":"At screening - prostatectomy","ValueMeaning":{"publicId":"3028675","version":"1","preferredName":"At screening - prostatectomy","longName":"3028675","preferredDefinition":"At screening - prostatectomy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"825F3F1F-34CB-D22E-E040-BB89AD4374D6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"825F3F1F-34E4-D22E-E040-BB89AD4374D6","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","deletedIndicator":"No"},{"value":"At screening - biopsy","valueDescription":"At screening - biopsy","ValueMeaning":{"publicId":"3028676","version":"1","preferredName":"At screening - biopsy","longName":"3028676","preferredDefinition":"At screening - biopsy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"825F3F1F-34EE-D22E-E040-BB89AD4374D6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"825F3F1F-3507-D22E-E040-BB89AD4374D6","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3028671","version":"1","preferredName":"Gleason Score for Prostate Cancer Timepoint Category","preferredDefinition":"A system of grading prostate cancer cells to determine the best treatment and to predict how well a person is likely to do. A low Gleason score means the cancer cells are very similar to normal prostate cells; a high Gleason score means the cancer cells are very different from normal. :A specific point in the time continuum, including those established relative to an event.:Category; used informally to mean a class of things.","longName":"C28084:C68568:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Timepoint","conceptCode":"C68568","definition":"A specific point in the time continuum, including those established relative to an event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"825F3F1F-3456-D22E-E040-BB89AD4374D6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"825F3F1F-3467-D22E-E040-BB89AD4374D6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"},{"publicId":"2812724","version":"1","longName":"Duke U New CDEs","context":"NCIP"}]},{"publicId":"3886752","version":"1","longName":"For Review","context":"DCI","ClassificationSchemeItems":[{"publicId":"3891931","version":"1","longName":"For Review","context":"DCI"}]}],"AlternateNames":[{"name":"DCI","type":"USED_BY","context":"DCI"}],"ReferenceDocuments":[{"name":"Gleason Score","type":"Preferred Question Text","description":"Gleason Score","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"825F3F1F-3511-D22E-E040-BB89AD4374D6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ZHANGWE","dateModified":"2013-09-13","changeDescription":"Curated to support Duke University Prostate cancer trials.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}